224 related articles for article (PubMed ID: 18495226)
1. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
Gotlieb WH; Saumet J; Beauchamp MC; Gu J; Lau S; Pollak MN; Bruchim I
Gynecol Oncol; 2008 Aug; 110(2):246-50. PubMed ID: 18495226
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins.
Yasmeen A; Beauchamp MC; Piura E; Segal E; Pollak M; Gotlieb WH
Gynecol Oncol; 2011 Jun; 121(3):492-8. PubMed ID: 21388661
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
5. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R
Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964
[TBL] [Abstract][Full Text] [Related]
7. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
Beauchamp MC; Knafo A; Yasmeen A; Carboni JM; Gottardis MM; Pollak MN; Gotlieb WH
Gynecol Oncol; 2009 Nov; 115(2):193-8. PubMed ID: 19699512
[TBL] [Abstract][Full Text] [Related]
8. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
[TBL] [Abstract][Full Text] [Related]
9. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
10. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
Treeck O; Wackwitz B; Haus U; Ortmann O
Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
13. Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatin‑resistant ovarian cancer.
Xie Y; Peng Z; Shi M; Ji M; Guo H; Shi H
Mol Med Rep; 2014 Nov; 10(5):2346-50. PubMed ID: 25118792
[TBL] [Abstract][Full Text] [Related]
14. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
15. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy.
Chiba Y; Sato S; Itamochi H; Yoshino N; Fukagawa D; Kawamura H; Suga Y; Kojima-Chiba A; Muraki Y; Sugai T; Sugiyama T
Int J Gynecol Cancer; 2017 Oct; 27(8):1666-1674. PubMed ID: 28786875
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells.
Zhang R; Zhang P; Wang H; Hou D; Li W; Xiao G; Li C
Stem Cell Res Ther; 2015 Dec; 6():262. PubMed ID: 26718286
[TBL] [Abstract][Full Text] [Related]
18. Proteasome Inhibitor MG132 Enhances Sensitivity to Cisplatin on Ovarian Carcinoma Cells In Vitro and In Vivo.
Guo N; Peng Z; Zhang J
Int J Gynecol Cancer; 2016 Jun; 26(5):839-44. PubMed ID: 27051056
[TBL] [Abstract][Full Text] [Related]
19. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR(R)) on human epithelial ovarian cancer cell line, OVCAR-3.
Bae SN; Lee YS; Kim MY; Kim JD; Park LO
Gynecol Oncol; 2006 Oct; 103(1):127-36. PubMed ID: 16624386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
